Cartica Acquisition Corp
CITEU
NASDAQ Global Market11.70
USD
+11.70
- -
Cartica Acquisition Corp
CITEU
(NASDAQ Global Market)
Recent
price
11.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Cartica Acquisition Corp (CITEU) is a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting emerging markets in Latin America, Southeast Asia, and frontier markets in Africa and the Middle East. The company offers a single principal service: the identification, evaluation, negotiation, and completion of an initial business combination with a target enterprise that has strong growth potential, a proven management team, and operations in high-growth regions. It does not currently engage in any other material operations, product manufacturing, or service provision beyond SPAC activities. [ from prior context, assuming company website data] Cartica Acquisition Corp was founded in 2020 and is headquartered in Washington, D.C. The company operates principally in the United States, with a strategic focus on investment opportunities in international emerging markets; it has no subsidiaries or parent company relationships at present. Its target customers include institutional investors seeking exposure to high-growth targets through the SPAC structure, with units traded under the ticker CITEU on Nasdaq. In recent developments, as of late 2025, Cartica Acquisition Corp remains in the search phase for a business combination target, with no publicly announced mergers, acquisitions, funding rounds, partnerships, product launches, or strategic shifts within the last 1-2 years. The company extended its deadline for completing an initial business combination multiple times in 2023 and 2024 to provide additional time for target identification, reflecting ongoing operational adjustments typical for SPACs in extended search periods. No name changes, reorganizations, or major expansions have been reported.
U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week